Q-omics provides the consensus-scored LINC02883 profile across patient tissues and cancer cell-line models. LINC02883 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC02883 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, LINC02883 RNA expression shows 16,468 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, STAD, and UVM as cancer lineages where LINC02883 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02883 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02883 survival associations across molecular data types. LINC02883 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02883 RNA expression–survival associations across cancer types. High LINC02883 expression shows unfavorable associations in UVM and ACC, but favorable associations in UCS, BLCA, MESO and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LINC02883 RNA expression.
This table summarizes LINC02883 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02883. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02883 shows lower tumor expression in BRCA and higher tumor expression in STAD, UCEC, COAD, READ and PRAD. The STAD box plot shows higher LINC02883 RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p < 0.001).
This table shows molecular features associated with LINC02883 in patient tissues and cancer cell lines. In patient samples, LINC02883 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
